AzTrials
AzTrials

Expectation Effects on Emotional ProcessingNCT07031804

Expectation Effects on Emotional Processing

A study testing Saline Nasal Spray in people with Expectation Effects on Emotional Processing, run by Universitätsklinikum Hamburg-Eppendorf at 1 site in Germany.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Understanding the mechanisms underlying expectation effects in the affective domain can provide valuable insights into possible therapeutic interventions for mood disorders. Studies have consistently found that expectations can influence emotional experiences. Read more about this study

Who is it for?
Ages 18 to 35 yearsHealthy volunteers can take part
What is being tested?
Saline Nasal Spray
Could I receive a placebo?
No, everyone receives an active treatment
How many people
51 participants
Where
1 siteGermany
Study dates
Jun 2025to Jan 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Aged 18-35 years
  • MRI compatible
  • Medical information and signed declaration of consent
  • Normal or corrected to normal vision
  • German speaking

Who cannot join

  • No informed consent
  • Current intake of central nervous system active drugs
  • Under influence of alcohol
  • BDI score above 12
  • Significant acute somatic or neurological diseases
  • History of psychiatric or neurological disorders
Show all 12Show fewer
  • Pregnancy/ breastfeeding
  • Acute nasal diseases or injuries
  • MR-specific exclusion criteria (claustrophobia, pacemaker, non-MR compatible metallic objects)
  • fMRI data with strong artefacts or excessive movement will be excluded from analysis
  • If a participant does not believe in the treatment on the screening day, they will not be included for the main study days
  • If a participant drops out after study day one, they will be excluded from the analysis

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Stefanie Brassen, Prof. Dr. contact

+49 407410 54865

sbrassen@uke.de

Lena Szabo, M.Sc. contact

+49 407410 58203

l.szabo@uke.de

Germany1 site
  • University Medical Center Hamburg-Eppendorf, Institute of Systems Neuroscience

    Hamburg, Free and Hanseatic City of Hamburg, 20251

    Stefanie Brassen, Prof. Dr., +49 407410 54865, sbrassen@uke.de

    Lena Szabo, M.Sc.

Other trials in Germany

About this study

Understanding the mechanisms underlying expectation effects in the affective domain can provide valuable insights into possible therapeutic interventions for mood disorders. Studies have consistently found that expectations can influence emotional experiences. Recently, it has been shown that top-down cognitive control is critical in inducing instruction-based affective placebo effects. However, changes in the emotional system over time not only rely on higher-level cognitive processes but also on more automatic mechanisms shaped by learning and past experiences. How such mechanisms are involved in affective placebo effects is relatively unknown, but is particularly interesting in light of findings showing that previous experiences of successful treatments are an important determinant of placebo responses.

This study aims to investigate the neurobehavioral mechanisms of how expectations and prior experiences modulate emotional processing. Healthy adults (N = 51, 50% women) will be recruited to participate in a cross-over fMRI study involving two conditions: positive expectation induction (placebo) and a control condition with no induced expectations. Participants will perform an emotion classification task under each condition. The investigators hypothesize that positive expectations enhance mood and improve the accuracy of recognizing happy facial expressions. Further, they hypothesize that affective expectations are represented in fMRI signal patterns in networks involved in face perception, emotional processing, and cognitive control.

Read the detailed description

Background:

Research demonstrated that positive expectations are related to a perception bias towards positive information and changes in neural networks of affective processing. However, it's unclear how underlying expectancy effects modulate response biases to emotional inputs. A recent study showed the importance of cognitive control and top-down regulation in expectation effects on emotional processing, mechanisms that may be less effective in cognitively vulnerable individuals, such as those with depression. Research on placebo analgesia indicates that not only such higher level-processes but also lower-level processes play a significant role in placebo effects. How such lower level processes are involved in affective placebo effects is relatively unknown but would be highly relevant given that long-term modulation of the emotional system also relies on computationally less costly bottom-up processes typically shaped by learning and experiences. Therefore, this study aims to investigate the neurobehavioral mechanisms of how expectations and prior experiences modulate emotional processing.

Recruitment plan:

Healthy participants will be recruited through an online advertisement on a voluntary basis. An initial short screening to assess basic eligibility (see inclusion and exclusion criteria) will take place over the phone, followed by an extensive screening on site, including the following questionnaires:

  • Demographics
  • Education
  • Generic rating scale for previous treatment experiences, treatment expectations, and treatment effects (G-EEE)
  • Beck Depression Inventory (BDI)

Design:

The study consists of three days: one screening day and two study days. On the screening day, in addition to assessing eligibility, participants will receive a saline nasal spray that is introduced as oxytocin. Treatment expectations will be induced via an established expectation induction protocol that systematically manipulates expectations in the context of face perception. Positive expectations about "oxytocin" will be induced via a video documentary detailing the mechanisms of oxytocin, highlighting its mood-enhancing effects and role in emotional processing. In detail, participants will complete a short training of an emotion classification task, view the video documentary, self-administer the nasal spray, rate their expectations using a visual analogue scale (VAS, from "no expected mood enhancement" to "strong expected mood enhancement"), and then complete the same training again. However, the second training is covertly manipulated and is designed to facilitate the detection of happy facial expressions. At the end of the day they will rate their experience with a VAS (from "experienced no positive mood change" to "experienced a large positive mood change"). This expectation induction combined with the covertly manipulated training is already implemented on the screening day to establish positive prior experiences associated with "oxytocin" and therefore enhance placebo effects on the study days. If a participant does not believe in the treatment on the screening day, they will not be included for the main study.

In a cross-over experiment, on two study days that are one week apart, participants will undergo fMRI scanning. Before scanning, participants will receive a saline nasal spray that is either introduced as oxytocin (placebo condition) or saline (control condition) in a counter-balanced design. Expectations will be reinforced via the video documentary. After the video, participants will receive verbal instructions about their assigned condition for that day (either "oxytocin" or control), self-administer the nasal spray, and rate their expectations. Depending on the assigned condition, participants will then either complete a standard training (control condition) or a covertly manipulated training ("oxytocin" condition). Participants will assess their current mood (using a VAS) at three time points: before nasal spray administration, after the manipulated training and after the fMRI scan. At the end of each study day, participants will rate their experience. While in the scanner, an emotion classification task is performed, in which participants label images of subtle emotional face expressions, varying in emotional intensity, as happy, fearful, or neutral. As a control measure, horizontal gaze trajectories (fixation and gaze shifts patterns) will be recorded using eye-tracking.

Hypotheses:

The investigators will examine the effects of positive expectations on mood state and task accuracy and investigate how positive expectations modulate uni- and multivariate fMRI signal patterns associated with the processing and categorization of emotional stimuli. More specifically, they hypothesize the following:

  • Positive expectations enhance mood and improve the accuracy of detecting subtle happy facial expressions.
  • fMRI patterns in sensory, affective, and cognitive areas in response to subtle happy faces are more similar to patterns evoked by unambiguous happy face localizers in the positive treatment expectation condition.
  • Pattern dissimilarity across happiness intensities decreases in the placebo condition.
  • Expectation effects on mood, happy face accuracy, and neural patterns are related to expectation ratings and measures of prior experience induced by the manipulated training.

Analysis plan:

For the behavioral analysis, statistical protocols developed in our lab will be applied, with a main focus on response threshold and sensitivity derived from psychometric functions. The effects of expectation on mood state and task accuracy and post-treatment experience will be assessed using statistical tests from the general linear model framework, including t-tests, repeated measures ANOVA and Pearson correlations. Statistical significance will be assumed based on an alpha value of 0.05. Emotion-specific psychometric response functions will be derived from regressing individual accuracy rates from the placebo condition on the control condition. The psychometric response functions will allow us to disentangle expectation effects with respect to response tendencies (intercept) and perceptual sensitivity (slope).

For the univariate fMRI analysis, a two-level random effects general linear model (GLM) approach will be employed, modeling task-related activity using the hemodynamic response function (HRF). Whole-brain analysis (cluster-level corrected) and a small-volume regions of interest (ROI) approach will be applied (p < .05 FWE corrected). A multivariate representational similarity analysis (RSA) approach will be used to compare the similarity of fMRI patterns during subtle emotional face presentation with patterns derived from unambiguous emotional face localizers. RSA protocols have previously been developed in our lab.

The here presented study is part of the collaborative research center (CRC) SFB/TRR289 and is funded by the Deutsche Forschungsgemeinschaft (DFG, ID: 422744262).

Being tested
Saline Nasal Spray
Keywords
Positive expectation, Treatment expectation, fMRI, Emotional processing, Placebo

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Saline Nasal SprayOther

    A saline nasal spray will be introduced as saline on the first day (no induced expectations) and as oxytocin on the second day (induced positive expectations)

  • Saline Nasal SprayOther

    A saline nasal spray will be introduced as oxytocin on the first day (induced positive expectations) and as saline on the second day (no induced positive expectations)

Study groups in NCT07031804
Study groupRoleWhat they receive
Placebo - ControlExperimentalParticipants in this group receive sham oxytocin on the first study day.
Receives: Other: Saline Nasal Spray
Control - PlaceboExperimentalParticipants in this group receive sham oxytocin on the second study day
Receives: Other: Saline Nasal Spray

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Effects of positive expectation on mood

    Mood ratings via visual analogue scale (VAS), consisting of a scale from 0 to 200 points (0 meaning unhappy; 200 meaning happy). VAS will be extracted as a raw score and then normalized to the baseline VAS. It will be analyzed to assess differences between interventions (placebo and control) and to evaluate changes over time throughout the experiment.

    Measured: On both day 1 and day 2, measurements will be taken before the intervention (VAS baseline), 5 minutes after nasal spray application, and after the scanning (~ 60 minutes after nasal spray application).

  2. Effects of positive expectation on task performance data

    Accuracies from the emotion classification task will be extracted and sampled for 3 emotional (happy, fearful and neutral) conditions for both interventions (Placebo and Control). Performance during the placebo condition will be regressed onto performance during the control condition for each emotion. The resulting emotion-specific psychometric response functions will allow us to disentangle expectation effects with respect to response tendencies (the intercept) and discrimination ability (the slope).

    Measured: Approximately 15 minutes after the nasal spray application, participants will perform an emotion classification task for 40 minutes while lying in the scanner on each day.

  3. Effects of positive expectation on blood oxygen level dependent (BOLD) signals

    Functional magnetic resonance imaging will be used to extract and analyze BOLD signals (regions of interest and whole brain) in response to the emotional conditions and interventions. Univariate and multivariate analyses will be performed to compare activation profiles and the similarity of fMRI patterns during placebo and control.

    Measured: Approximately 15 minutes after the nasal spray application, participants will lie in the scanner for ~ 40 minutes while performing the emotion classification task on each day.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jun 2025
  2. Study startJun 2025 (estimated)
  3. Primary completionJan 2026 (estimated)
  4. Study completionJan 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Model description
A cross-over design will be employed by giving a saline nasal spray introduced either as oxytocin or as saline.
Masking
Single blind
Who is masked
Participant
Enrolment
51 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07031804
Sponsor's protocol ID
Exface
Status last verified
Jun 2025
First submitted
4 Jun 2025
Last updated
27 Jun 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Publications

  • Mostauli A, Rauh J, Gamer M, Buchel C, Rief W, Brassen S. Placebo treatment entails resource-dependent downregulation of negative inputs. Sci Rep. 2025 Mar 17;15(1):9088. doi: 10.1038/s41598-025-93589-y.

    PubMed 40097556
  • Baker J, Gamer M, Rauh J, Brassen S. Placebo induced expectations of mood enhancement generate a positivity effect in emotional processing. Sci Rep. 2022 Mar 29;12(1):5345. doi: 10.1038/s41598-022-09342-2.

    PubMed 35351936

Questions about this trial

What is this clinical trial studying?

A study testing Saline Nasal Spray in people with Expectation Effects on Emotional Processing, run by Universitätsklinikum Hamburg-Eppendorf at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 27 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Stefanie Brassen, Prof. Dr. (+49 407410 54865, sbrassen@uke.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Effects of positive expectation on mood (time frame: On both day 1 and day 2, measurements will be taken before the intervention (VAS baseline), 5 minutes after nasal spray application, and after the scanning (~ 60 minutes after nasal spray application).). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07031804, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jun 2025; AzTrials last refreshed its copy on 28 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in